Re: Aducanumab-Related ARIA: Paean or Lament?
作者信息
Høilund-Carlsen Poul F, Alavi Abass, Revheim Mona-Elisabeth
机构信息
Department of Radiology Hospital of the University of Pennsylvania Philadelphia, PA.
Division of Radiology and Nuclear Medicine Oslo University Hospital; Institute of Clinical Medicine, University of Oslo Oslo, Norway
出版信息
Clin Nucl Med. 2023 Jun 1;48(6):505-506. doi: 10.1097/RLU.0000000000004509. Epub 2023 Feb 1.
Abstract
摘要
相似文献
1
Re: Aducanumab-Related ARIA: Paean or Lament?关于：与阿杜卡单抗相关的淀粉样蛋白相关成像异常（ARIA）：赞歌还是挽歌？
Clin Nucl Med. 2023 Jun 1;48(6):505-506. doi: 10.1097/RLU.0000000000004509. Epub 2023 Feb 1.
2
Re: Aducanumab-Related ARIA: Paean or Lament?关于：与阿杜卡单抗相关的淀粉样蛋白相关成像异常（ARIA）：赞歌还是挽歌？
Clin Nucl Med. 2023 Feb 1;48(2):168-169. doi: 10.1097/RLU.0000000000004490. Epub 2022 Nov 11.
3
Commentary: Aducanumab-Related ARIA: Paean or Lament?述评：阿杜卡奴单抗相关 ARIA：赞歌还是悲歌？
Clin Nucl Med. 2022 Aug 1;47(8):707-709. doi: 10.1097/RLU.0000000000004252. Epub 2022 May 11.
4
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?阿杜卡奴单抗相关淀粉样蛋白相关影像学异常：赞歌还是悲歌？
Clin Nucl Med. 2022 Jul 1;47(7):625-626. doi: 10.1097/RLU.0000000000004250. Epub 2022 Apr 22.
5
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.在两项评估早期阿尔茨海默病患者使用 aducanumab 的 3 期研究中，淀粉样蛋白相关成像异常。
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
6
A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.在早期阿尔茨海默病患者中使用 aducanumab 后，淀粉样蛋白相关影像学异常的时间事件暴露-反应模型。
J Clin Pharmacol. 2022 Aug;62(8):1030-1046. doi: 10.1002/jcph.2047. Epub 2022 Apr 4.
7
Aducanumab: Appropriate use recommendations.阿杜卡单抗：合理使用建议。
Alzheimers Dement. 2022 Mar;18(3):531-533. doi: 10.1002/alz.12444. Epub 2021 Jul 27.
8
Aducanumab: Appropriate Use Recommendations Update.阿杜卡奴单抗：合理使用建议更新。
J Prev Alzheimers Dis. 2022;9(2):221-230. doi: 10.14283/jpad.2022.34.
9
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.接受加速批准的 aducanumab 治疗后出现淀粉样蛋白相关影像学异常的初步经验。
J Prev Alzheimers Dis. 2023;10(4):765-770. doi: 10.14283/jpad.2023.96.
10
Re: Aducanumab-Related ARIA: Paean or Lament?: Erratum.
Clin Nucl Med. 2023 Apr 1;48(4):380. doi: 10.1097/RLU.0000000000004624.
引用本文的文献
1
Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?阿尔茨海默病淀粉样蛋白假说和抗体疗法：冰川消融？
Int J Mol Sci. 2024 Mar 31;25(7):3892. doi: 10.3390/ijms25073892.
2
FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls.18F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）与淀粉样蛋白正电子发射断层扫描（Amyloid-PET）在阿尔茨海默病诊断及疗效评估中的应用：优势与局限
Diagnostics (Basel). 2023 Jul 3;13(13):2254. doi: 10.3390/diagnostics13132254.
Zotero 插件